6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura

      research-article
      , M.D. 1 , 2 , 3 , 4 , 5 , , D.Phil. 6 , 7 , , M.D., Ph.D. 8 , , M.D., Ph.D. 5 , 6 , , B.A. 3 , , B.S. 3 , , B.A. 8 , , M.D., Ph.D. 5 , 6 , , M.D., M.P.H. 5 , 9 , , M.D., M.B.A. 5 , 9 , , M.D. 3 , 5 , , B.S., B.A. 3 , 5 , , M.D. 5 , 10 , , M.D., Ph.D. 5 , 6 , , M.D. 11 , , M.D. 12 , , M.D. 13 , , Ph.D., M.D. 13 , , D.O., M.P.H. 1 , 5 , , M.D. 8 , , M.D., D.Phil. 1 , 5 , , M.D. 2 , 5 , , M.D. 5 , 6 , , M.D. 1 , 2 , 5 , , M.D., Ph.D. 1 , 5 , , M.D., Ph.D. 1 , 5
      The New England journal of medicine

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          In immune thrombotic thrombocytopenic purpura (iTTP), autoantibodies against the metalloprotease ADAMTS13 lead to catastrophic microvascular thrombosis. However, the potential benefits of recombinant human ADAMTS13 (rADAMTS13) in iTTP remain unknown. We report the clinical use of rADAMTS13 in iTTP. Administration of rADAMTS13 was associated with rapid suppression of disease activity and complete recovery in a critically ill patient whose condition had proven refractory to all available treatments. We show that rADAMTS13 causes immune complex formation, saturating the autoantibody and likely promoting its clearance. Our data support the role of rADAMTS13 as a novel adjunctive therapy in iTTP.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Syndromes of thrombotic microangiopathy.

          This review article covers the diverse pathophysiological pathways that can lead to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys and other organs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.

            Among the syndromes characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe deficiency in the ADAMTS13 enzyme. Patients with this disorder need urgent treatment with plasma exchange. Because ADAMTS13 activity testing typically requires prolonged turnaround times and might be unavailable in resource-poor settings, a method to rapidly assess the likelihood of severe ADAMTS13 deficiency is needed.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

                Bookmark

                Author and article information

                Journal
                0255562
                5985
                N Engl J Med
                N Engl J Med
                The New England journal of medicine
                0028-4793
                1533-4406
                22 May 2024
                09 May 2024
                26 May 2024
                : 390
                : 18
                : 1690-1698
                Affiliations
                [1. ]Blood Transfusion Service, Massachusetts General Hospital, Boston, MA
                [2. ] Division of Hematology, Massachusetts General Hospital, Boston, MA
                [3. ]Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA
                [4. ]The Broad Institute of MIT and Harvard, Cambridge, MA
                [5. ]Harvard Medical School, Boston, MA
                [6. ]Department of Pathology, Massachusetts General Hospital, Boston, MA
                [7. ]Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA
                [8. ]Versiti Blood Center of Wisconsin, Milwaukee, WI
                [9. ]Cardiology Division, Massachusetts General Hospital, Boston, MA
                [10. ]Division of Hematology and Apheresis Service, Beth Israel Deaconess Medical Center, Boston, MA
                [11. ]Division of Hematology and Oncology, Lahey Hospital and Medical Center, Burlington, MA
                [12. ]Department of Hematology and Clinical Oncology, UMass Chan Medical School-Baystate Health, Springfield, MA
                [13. ]Department of Pathology, Transfusion/Apheresis Medicine Services, UMass Chan Medical School-Baystate Health, Springfield, MA
                Author notes
                Corresponding Author: Pavan K. Bendapudi, M.D., Center for Life Science, Room 906, 3 Blackfan Circle, Boston, MA 02115, pbendapudi@ 123456mgb.org
                Article
                NIHMS1983589
                10.1056/NEJMoa2402567
                11128310
                38718359
                62e197e8-cd77-4482-9bf0-fcf5491b1393

                This Author Accepted Manuscript is licensed for use under the CC-BY-NC-ND license.

                History
                Categories
                Article

                Comments

                Comment on this article